Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
Public ClinicalTrials.gov record NCT00700206. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Randomized Study Comparing Two Dose Schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) in Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented significant cytopenia for at least two months by the IWG criteria are eligible.
Study identification
- NCT ID
- NCT00700206
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2008
- Primary completion
- Jun 30, 2011
- Completion
- Jun 30, 2011
- Last update posted
- Oct 11, 2011
2008 – 2011
United States locations
- U.S. sites
- 36
- U.S. states
- 15
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center | Tucson | Arizona | 85724-5024 | — |
| Central Hematology Oncology Medical Group, Inc. | Alhambra | California | 91801 | — |
| St. Jude Heritage Healthcare | Fullerton | California | 92835 | — |
| Wilshire Oncology Medical Group, Inc. | La Verne | California | 91750 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Clinical Trials and Research Associates, Inc. | Montebello | California | 90640 | — |
| North Valley Hematology/Oncology Medical Group | Northridge | California | 91325 | — |
| Bay Area Cancer Research Group | Pleasant Hill | California | 94523 | — |
| Desert Hematology Oncology Medical Group | Rancho Mirage | California | 92270 | — |
| Cancer Care Associates Medical Group, Inc. | Redondo Beach | California | 92077 | — |
| Sansum Clinic | Santa Barbara | California | 93105 | — |
| Santa Barbara Hematology Medical Group, Inc. | Santa Barbara | California | 93105 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| University of Colorado at Denver Health Sciences Center | Aurora | Colorado | 80445 | — |
| The Center for Hematology Oncology | Boca Raton | Florida | 33486 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northeast Georgia Cancer Care, LLC | Athens | Georgia | 30607 | — |
| Suburban Hematology-Oncology Associates, P.C. | Lawrenceville | Georgia | 30045 | — |
| Joliet Oncology-Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Loyola University Chicago | Maywood | Illinois | 60153 | — |
| Southern Illinois University School of Medicine | Springfield | Illinois | 62702 | — |
| Central Hematology Oncology Medical Group, Inc. | Terre Haute | Indiana | 47802 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| St. Vincent's Comprehensive Cancer Center | New York | New York | 10011 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Case Western Reserve University/University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Hematology & Medical Oncology | Cleveland | Ohio | 44195 | — |
| The University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Cancer Care Associates | Oklahoma City | Oklahoma | 73112 | — |
| Cancer Care Associates | Tulsa | Oklahoma | 74136 | — |
| Kaiser Permanente | Portland | Oregon | 97227 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00700206, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2011 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00700206 live on ClinicalTrials.gov.